^
Association details:
| Biomarker: | miR-34a overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Mir-34a as predictor of immunotherapy efficacy in NSCLC patients
Published date:
05/19/2021
Excerpt:
Patients with low miR-34a expression levels were associated with shorter progression free survival (PFS) and overall survival (OS) compared to patients with high 34a expression (1.97 vs 6.33 months; p = 0.042 and 2.93 vs 9,60 months; p = 0.012, respectively)....findings suggest that circulating miR-34a may serve as a potential predictive biomarker in NSCLC patients treated with immunotherapy.
DOI:
10.1200/JCO.2021.39.15_suppl.e21191
